Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
$6.90
-5.6%
$11.25
$2.08
▼
$15.37
$3.19B0.8815.55 million shs9.90 million shs
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
$93.82
+0.3%
$83.53
$37.02
▼
$99.31
$7.37B0.07697,111 shs366,978 shs
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
$112.48
-3.7%
$97.93
$74.50
▼
$122.20
$7.80B2.17869,676 shs1.19 million shs
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
$23.91
-4.5%
$28.14
$13.50
▼
$44.60
$1.62B-0.88773,503 shs287,118 shs
10 Stocks Powering The Next AI Boom  Cover

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
-2.27%-4.19%-50.81%-11.82%+223.45%
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
-1.59%-2.85%+12.47%+18.36%+121.87%
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
-1.88%+6.32%+29.49%+6.18%+13.23%
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
-5.22%-9.41%-11.14%-22.45%-32.60%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
$6.90
-5.6%
$11.25
$2.08
▼
$15.37
$3.19B0.8815.55 million shs9.90 million shs
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
$93.82
+0.3%
$83.53
$37.02
▼
$99.31
$7.37B0.07697,111 shs366,978 shs
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
$112.48
-3.7%
$97.93
$74.50
▼
$122.20
$7.80B2.17869,676 shs1.19 million shs
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
$23.91
-4.5%
$28.14
$13.50
▼
$44.60
$1.62B-0.88773,503 shs287,118 shs
10 Stocks Powering The Next AI Boom  Cover

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
-2.27%-4.19%-50.81%-11.82%+223.45%
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
-1.59%-2.85%+12.47%+18.36%+121.87%
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
-1.88%+6.32%+29.49%+6.18%+13.23%
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
-5.22%-9.41%-11.14%-22.45%-32.60%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
2.71
Moderate Buy$13.80100.00% Upside
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
2.80
Moderate Buy$102.389.12% Upside
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
2.77
Moderate Buy$141.6725.95% Upside
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
2.56
Moderate Buy$46.7195.38% Upside

Current Analyst Ratings Breakdown

Latest ZBIO, IOVA, KNSA, and RYTM Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
11/20/2026
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
Reiterated RatingMarket Outperform
11/20/2026
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
Lower Price TargetMarket Outperform$166.00 ➝ $160.00
11/18/2026
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
UpgradeSell (E+) ➝ Sell (D-)
11/17/2026
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
Boost Price TargetBuy$100.00 ➝ $115.00
11/6/2026
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
Boost Price TargetOverweight$18.00 ➝ $19.00
11/6/2026
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
Boost Price TargetMarket Outperform$8.00 ➝ $12.00
11/6/2026
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
Lower Price TargetOverweight$145.00 ➝ $142.00
11/5/2026
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
Boost Price TargetBuy$143.00 ➝ $147.00
11/4/2026
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
DowngradeSell (D-) ➝ Sell (E+)
11/4/2026
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
Reiterated RatingMarket Perform
11/4/2026
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
Reiterated RatingOutperform
(Data available from 11/20/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
$378.98M8.42N/AN/A$1.76 per share3.92
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
$677.56M10.88$0.78 per share119.75$9.04 per share10.38
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
$189.76M41.10N/AN/A$1.27 per share88.57
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
$10M162.16N/AN/A$3.13 per share7.64
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
-$390.98M-$0.53N/AN/AN/A-58.20%-29.71%-23.55%N/A
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
$59.01M$1.3072.1762.13N/A11.58%17.27%12.64%N/A
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
-$196.54M-$2.90N/AN/AN/A-69.03%-171.16%-43.00%N/A
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
-$377.74M-$9.42N/AN/AN/AN/A-144.65%-59.83%N/A

Latest ZBIO, IOVA, KNSA, and RYTM Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/5/2026Q3 2026
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
-$0.09-$0.05+$0.04-$0.05$115.98 million$121.47 million
11/5/2026Q3 2026
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
-$1.24-$1.65-$0.41-$1.65$10.00 million$10.00 million
11/3/2026Q3 2026
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
-$0.7097-$0.61+$0.0997-$0.61$85.56 million$92.13 million
10/27/2026Q3 2026
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
$0.3710$0.56+$0.1890$0.56$260.66 million$285.97 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
N/AN/AN/AN/AN/A
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
N/AN/AN/AN/AN/A
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
N/AN/AN/AN/AN/A
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
N/A
5.20
4.67
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
N/A
3.91
3.35
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
N/A
2.78
2.57
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
1.88
9.42
9.42
CompanyEmployeesShares OutstandingFree FloatOptionable
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
975462.66 million426.57 millionOptionable
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
36678.57 million37.73 millionOptionable
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
41469.33 million65.24 millionOptionable
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
16767.82 million52.90 millionOptionable

Recent News About These Companies

FY2026 EPS Forecast for Zenas BioPharma Decreased by Analyst
Zenas BioPharma Highlights New Phase 3 Obexelimab Data

New MarketBeat Followers Over Time

Media Sentiment Over Time

Iovance Biotherapeutics stock logo

Iovance Biotherapeutics NASDAQ:IOVA

$6.90 -0.41 (-5.61%)
Closing price 03:59 PM Eastern
Extended Trading
$6.90 0.00 (0.00%)
As of 04:05 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma. It also develops lifileucel in combination with pembrolizumab to treat frontline advanced melanoma patients; LN-145 for the treatment of non-small cell lung cancer (NSCLC) and solid tumor cancers; IOV-4001, which is in Phase 1/2 IOV-GM1-201 clinical trial, for the treatment of NSCLC; and lifileucel for gynecological cancers. The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.

Kiniksa Pharmaceuticals International stock logo

Kiniksa Pharmaceuticals International NASDAQ:KNSA

$93.82 +0.28 (+0.30%)
Closing price 03:58 PM Eastern
Extended Trading
$93.89 +0.07 (+0.08%)
As of 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. The company was incorporated in 2015 and is based in Hamilton, Bermuda.

Rhythm Pharmaceuticals stock logo

Rhythm Pharmaceuticals NASDAQ:RYTM

$112.48 -4.32 (-3.70%)
Closing price 03:59 PM Eastern
Extended Trading
$112.44 -0.04 (-0.04%)
As of 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

Zenas BioPharma stock logo

Zenas BioPharma NASDAQ:ZBIO

$23.91 -1.13 (-4.51%)
Closing price 03:58 PM Eastern
Extended Trading
$23.85 -0.06 (-0.25%)
As of 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Zenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company, which engages in the development and commercialization of transformative immunology-based therapies for patients. The company was founded by Lonnie O. Moulder Jr on November 12, 2019 and is headquartered in Waltham, MA.